Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide.

NCT02279654 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02279654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02279654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide.
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
December 17, 2014
Completion date
March 29, 2022
Enrollment
389 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome